David J Feith
Overview
Explore the profile of David J Feith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moosic K, Olson T, Freijat M, Khalique S, Hamele C, Shemo B, et al.
Front Immunol
. 2024 Nov;
15:1466276.
PMID: 39497832
Objectives: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells frequent somatic activating mutations. Based on the disease overlap between LGL leukemia...
2.
Ung J, Kassai M, Tan S, Loughran Jr T, Feith D, Cabot M
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337312
The tumor-suppressor sphingolipid ceramide is recognized as a key participant in the cytotoxic mechanism of action of many types of chemotherapy drugs, including anthracyclines, Vinca alkaloids, the podophyllotoxin etoposide, taxanes,...
3.
Pal I, Illendula A, Joyner A, Manavalan J, Deddens T, Sabzevari A, et al.
bioRxiv
. 2024 Jul;
PMID: 39071370
Histone deacetylase (HDAC) inhibitors are a widely recognized and valued treatment option for patients with relapsed or refractory peripheral T cell lymphomas (PTCL). Romidepsin is a relatively selective Class I...
4.
Hagen J, Montgomery M, Aruleba R, Chrest B, Green T, Kassai M, et al.
bioRxiv
. 2024 Apr;
PMID: 38659944
Despite early optimism, therapeutics targeting oxidative phosphorylation (OxPhos) have faced clinical setbacks, stemming from their inability to distinguish healthy from cancerous mitochondria. Herein, we describe an actionable bioenergetic mechanism unique...
5.
Casasampere M, Ung J, Inanez A, Dufau C, Tsuboi K, Casas J, et al.
J Lipid Res
. 2024 Feb;
65(3):100520.
PMID: 38369184
Lipid amidases of therapeutic relevance include acid ceramidase (AC), N-acylethanolamine-hydrolyzing acid amidase, and fatty acid amide hydrolase (FAAH). Although fluorogenic substrates have been developed for the three enzymes and high-throughput...
6.
Assatova B, Willim R, Trevisani C, Haskett G, Kariya K, Chopra K, et al.
Clin Cancer Res
. 2024 Jan;
30(11):2514-2530.
PMID: 38252421
Purpose: Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms. Experimental Design: Primary specimens, cell lines, patient-derived xenograft models, commercially available, and proprietary anti-KLRG1...
7.
Paudel B, Tan S, Fox T, Ung J, Golla U, Shaw J, et al.
Blood Adv
. 2024 Jan;
8(5):1137-1142.
PMID: 38170742
No abstract available.
8.
Ung J, Tan S, Fox T, Shaw J, Taori M, Horton B, et al.
Cancers (Basel)
. 2023 Dec;
15(24.
PMID: 38136410
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell-death-promoting signaling lipid that plays a central role in therapy-induced cell death. We previously...
9.
Ung J, Tan S, Fox T, Shaw J, Taori M, Horton B, et al.
bioRxiv
. 2023 Nov;
PMID: 37961314
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy requiring urgent treatment advancements. Ceramide is a cell death-promoting signaling lipid that plays a central role in therapy-induced cell death. Acid...
10.
Paudel B, Tan S, Fox T, Ung J, Shaw J, Dunton W, et al.
bioRxiv
. 2023 May;
PMID: 37131653
Acute myeloid leukemia (AML) is an aggressive disease with complex and heterogeneous biology. Although several genomic classifications have been proposed, there is a growing interest in going beyond genomics to...